Pregnancy, baby, and childhood outcomes from using anti-seizure medication during pregnancy

Tools

Moore, Emily and Millar, Morven and Merrick, Rachel and Mueller, Tanja and Stark, Victoria and Jarvis, Lynne and Kurdi, Amanj and Hopkins, Leanne and McTaggart, Stuart and Vieira, Rute and Bennie, Marion and Wood, Rachael (2026) Pregnancy, baby, and childhood outcomes from using anti-seizure medication during pregnancy. Communications Medicine, 6 (1). 28. ISSN 2730-664X (https://doi.org/10.1038/s43856-025-01285-9)

[thumbnail of Moore-etal-CM-2025-Pregnancy-baby-and-childhood-outcomes-from-using-anti-seizure-medication-during-pregnancy]
Preview
 Text. Filename: Moore-etal-CM-2025-Pregnancy-baby-and-childhood-outcomes-from-using-anti-seizure-medication-during-pregnancy.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (1MB)| Preview

Abstract

Background: Evidence of the safety of some anti-seizure medicines (ASMs) during pregnancy remains uncertain. Methods: We conducted a population-based cohort study of singleton pregnancies in Scotland conceived between 01/04/2010-02/07/2023. Exposure was ‘Any ASM’ prescription issued 28 days prior to conception up to pregnancy end. Seven monotherapies were also examined: valproate, topiramate, carbamazepine, lamotrigine, levetiracetam, gabapentin, and pregabalin. Unexposed comparators were matched to the exposed on gestational age and year of conception. Pregnancy loss, congenital condition, and child development outcomes were compared by exposure status using conditional logistic regression to account for the matched study design. Results: Here we show pregnancy loss (3,175/11,011 pregnancies, 28.8% vs. 24,040/107,889 pregnancies, 22.3%), congenital conditions (230/8,370 babies, 2.7% vs. 1,693/82,085 babies, 2.1%) and developmental concerns (1,270/4,890 live births, 26.0% vs. 7,658/48,883 live births, 15.7%) are more common following any ASM exposure in pregnancy compared with no ASM exposure in pregnancy. Valproate is strongly associated with pregnancy loss (adjusted odds ratio (aOR): 1.92, 95% confidence interval (CI): 1.50-2.47), congenital conditions (aOR: 1.85, 95% CI: 1.06-3.21) and developmental concerns (aOR: 1.43, 95% CI: 1.01-2.03). Pregabalin, gabapentin, and Any ASM are also associated with pregnancy loss and developmental concerns. Conclusions: Our findings corroborate the associated risks of valproate use and embryo malformations, support the use of lamotrigine and levetiracetam in pregnancy, and raise concerns regarding gabapentinoid use in pregnancy.

ORCID iDs

Moore, Emily, Millar, Morven, Merrick, Rachel, Mueller, Tanja ORCID logoORCID: https://orcid.org/0000-0002-0418-4789, Stark, Victoria, Jarvis, Lynne, Kurdi, Amanj ORCID logoORCID: https://orcid.org/0000-0001-5036-1988, Hopkins, Leanne, McTaggart, Stuart, Vieira, Rute, Bennie, Marion ORCID logoORCID: https://orcid.org/0000-0002-4046-629X and Wood, Rachael;
CORE (COnnecting REpositories)